Approach to the patient with anaplastic thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 8, 2012, Pages 2566-2572

  Smallridge, Robert C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB;

ADULT; ASPIRATION BIOPSY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISTANT METASTASIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHAGIA; ECHOGRAPHY; EXPECTATION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HOARSENESS; HOSPICE CARE; HUMAN; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; NECK DISSECTION; NECK TUMOR; PATIENT PREFERENCE; PATIENT REFERRAL; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC ERROR; THYROID CARCINOMA; THYROID GLAND; THYROIDECTOMY; TRACHEOSTOMY; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR LOCALIZATION; TUMOR VOLUME;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; THYROID NEOPLASMS;

CANDIDA;

EID: 84864801691     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1314     Document Type: Review

References (48)

1. Siegel R, Ward E, Brawley O, Jemal A 2011 Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236
2. Al-Hamdan N, Ravichandran K, Al-Sayyad J, Al-Lawati J, Khazal Z, Al-Khateeb F, Abdulwahab A, Al-Asfour A 2009 Incidence of cancer in Gulf Cooperation Council countries, 1998-2001. East Mediterr Health J 15:600-611
3. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, Park EC, Lee JS 2010 Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci 25:1113-1121
4. Smallridge RC, Abate E, Anaplastic thyroid carcinoma: clinical aspects. In: Wartofsky L, Van Nostrand D, eds. Thyroid cancer: a comprehensive guide to clinical management. 3rd ed (in press). New York: Springer
5. Smallridge RC, Marlow LA, Copland JA 2009 Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16:17-44
6. Smallridge RC, Copland JA 2010 Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 22:486-497
7. Abate EG, Smallridge RC 2011 Managing anaplastic thyroid carcinoma. Expert Rev Endocrinol Metab 6:793-809
8. Smallridge RC, Abate E, Anaplastic thyroid carcinoma: prognosis. In: Wartofsky L, Van Nostrand D, eds. Thyroid cancer: a comprehensive guide to clinical management. 3rd ed (in press). New York: Springer
9. Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, El-Naggar AK 2008 Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol 39:15-20 (Pubitemid 350216164)
10. Ensinger C, Spizzo G, Moser P, Tschoerner I, Prommegger R, Gabriel M, Mikuz G, Schmid KW 2004 Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann NY Acad Sci 1030:69-77 (Pubitemid 40378898)
11. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN 2004 Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10:8594-8602 (Pubitemid 40053427)
12. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B 2007 Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 14:719-729 (Pubitemid 46175318)
13. Kurebayashi J, Okubo S, Yamamoto Y, Ikeda M, Tanaka K, Otsuki T, Sonoo H 2006 Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol 58:460-470 (Pubitemid 43999794)
14. Nobuhara Y, Onoda N, Yamashita Y, Yamasaki M, Ogisawa K, Takashima T, Ishikawa T, Hirakawa K 2005 Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 92:1110-1116 (Pubitemid 40546677)
15. Hoffmann S, Burchert A, Wunderlich A, Wang Y, Lingelbach S, Hofbauer LC, Rothmund M, Zielke A 2007 Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine 31:105-113 (Pubitemid 350195142)
16. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R 2012 Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100-103
17. Nguyen BD, Ram PC 2007 PET/CT staging and posttherapeutic monitoring of anaplastic thyroid carcinoma. Clin Nucl Med 32:145-149 (Pubitemid 46148402)
18. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, Reading CC, Hay ID, Lowe VJ 2008 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid 18:713-719 (Pubitemid 352009926)
19. Poisson T, Deandreis D, Leboulleux S, Bidault F, Bonniaud G, Baillot S, Aupérin A, Al Ghuzlan A, Travagli JP, Lumbroso J, Baudin E, Schlumberger M 2010 18F-Fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging 37:2277-2285
20. Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, Shimizu K, Ito K, Ito K 2011 Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 21:1183-1189
21. Ito K, Hanamura T, Murayama K, Okada T, Watanabe T, Harada M, Ito T, Koyama H, Kanai T, Maeno K, Mochizuki Y, Amano J 2012 Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck 34:230-237
22. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR 2001 Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130:1028-1034 (Pubitemid 34014569)
23. Passler C, Scheuba C, Prager G, Kaserer K, Flores JA, Vierhapper H, Niederle B 1999 Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis. Langenbecks Arch Surg 384:284-293 (Pubitemid 29309073)
24. Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC 2009 Multimodality treatment for anaplastic thyroid carcinoma-treatment outcome in 75 patients. Radiother Oncol 92:100-104
25. De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B, Schlumberger M 2004 Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 60:1137-1143 (Pubitemid 39440799)
26. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A 2005 Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103:1330-1335 (Pubitemid 40410726)
27. Chen J, Tward JD, Shrieve DC, Hitchcock YJ 2008 Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol 31:460-464
28. Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, Hjelm Skog AL, Wallin G 2002 Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86:1848-1853
29. Dandekar P, Harmer C, Barbachano Y, Rhys-Evans P, Harrington K, Nutting C, Newbold K 2009 Hyperfractionated accelerated radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis. Int J Radiat Oncol Biol Phys 74:518-521
30. Wong CS, Van Dyk J, Simpson WJ 1991 Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 20:3-9
31. Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, Evans DB, Clayman G, Sherman SI, Schwartz DL 2010 Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy. Head Neck 32:829-836
32. Nutting CM, Convery DJ, Cosgrove VP, Rowbottom C, Vini L, Harmer C, Dearnaley DP, Webb S 2001 Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland. Radiother Oncol 60:173-180 (Pubitemid 32605696)
33. Wang Y, Tsang R, Asa S, Dickson B, Arenovich T, Brierley J 2006 Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 107:1786-1792 (Pubitemid 44582947)
34. Tan RK, Finley 3rd RK, Driscoll D, Bakamjian V, Hicks Jr WL, Shedd DP 1995 Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 17:41-47; discussion 47-48
35. Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ 2002 The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 9:57-64 (Pubitemid 34262898)
36. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160 (Pubitemid 16236586)
37. Ain KB, Egorin MJ, DeSimone PA 2000 Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-sixhour infusion. Collaborative anaplastic thyroid cancer health intervention trials (CATCHIT) group. Thyroid 10:587-594 (Pubitemid 30670619)
38. Higashiyama T, Ito Y, Hirokawa M, Fukushima M, Uruno T, Miya A, Matsuzuka F, Miyauchi A 2010 Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20:7-14
39. Troch M, Koperek O, Scheuba C, Dieckmann K, Hoffmann M, Niederle B, Raderer M 2010 High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab 95:E54-E57
40. Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC 2011 Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 21:25-30
41. Mooney CJ, Nagaiah G, Fu P, Wasman JK, Cooney MM, Savvides PS, Bokar JA, Dowlati A,Wang D, Agarwala SS, Flick SM, Hartman PH, Ortiz JD, Lavertu PN, Remick SC 2009 A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19:233-240
42. Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, Giordano T, Worden FP 2010 A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 20:975-980
43. Hogan T, Jing Jie Yu, Williams HJ, Altaha R, Xiaobing Liang, Qi He 2009 Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. J Oncol Pharm Pract 15:111-117
44. Masago K, Miura M, Toyama Y, Togashi Y, Mishima M 2011 Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic Mutation, L858R, in exon 21. J Clin Oncol 29:e465-e467
45. Fury MG, Solit DB, Su YB, Rosen N, Sirotnak FM, Smith RP, Azzoli CG, Gomez JE, Miller VA, Kris MG, Pizzo BA, Henry R, Pfister DG, Rizvi NA 2007A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 59:467-475 (Pubitemid 46122325)
46. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ 2008 A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18:317-323 (Pubitemid 351415790)
47. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY, Clark OH 2001 Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91:2335-2342 (Pubitemid 32552820)
48. Kihara M, Miyauchi A, Yamauchi A, Yokomise H 2004 Prognostic factors of anaplastic thyroid carcinoma. Surg Today 34:394-398 (Pubitemid 38626484)